Alkermes plc. (ALKS) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Alkermes plc. Do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Alkermes plc. (ALKS) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Richard F. Pops and employs approximately 2,280 people. With a market capitalization of $5.8B, ALKS is one of the notable companies in the Healthcare sector.
Alkermes plc. (ALKS) Stock Rating — Hold (April 2026)
As of April 2026, Alkermes plc. receives a Hold rating with a composite score of 44.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ALKS ranks #877 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Alkermes plc. ranks #62 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ALKS Stock Price and 52-Week Range
Alkermes plc. (ALKS) currently trades at $33.48. The stock lost $1.44 (4.1%) in the most recent trading session. The 52-week high for ALKS is $36.32, which means the stock is currently trading -7.8% from its annual peak. The 52-week low is $25.16, putting the stock 33.0% above its annual trough. Recent trading volume was 2.0M shares, reflecting moderate market activity.
Is ALKS Overvalued or Undervalued? — Valuation Analysis
Alkermes plc. (ALKS) carries a value factor score of 58/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 19.28x, compared to the Healthcare sector average of 23.63x — a discount of 18%. The price-to-book ratio stands at 3.02x, versus the sector average of 2.75x. The price-to-sales ratio is 3.74x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ALKS trades at 18.26x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 14.30x.
Overall, ALKS's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Alkermes plc. Profitability — ROE, Margins, and Quality Score
Alkermes plc. (ALKS) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 15.7%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 11.5% versus the sector average of -33.1%.
On a margin basis, Alkermes plc. reports gross margins of 85.4%, compared to 71.5% for the sector. The operating margin is 19.7% (sector: -66.1%). Net profit margin stands at 18.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -1.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ALKS Debt, Balance Sheet, and Financial Health
Alkermes plc. has a debt-to-equity ratio of 37.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.55x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $616M.
ALKS has a beta of 0.73, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Alkermes plc. is 59/100, reflecting average volatility within the normal range for its sector.
Alkermes plc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Alkermes plc. reported revenue of $1.47B and earnings per share (EPS) of $1.47. Net income for the quarter was $285M. Gross margin was 85.4%. Operating income came in at $301M.
In FY 2025, Alkermes plc. reported revenue of $1.48B and earnings per share (EPS) of $1.47. Net income for the quarter was $242M. Gross margin was 86.7%. Revenue grew -5.2% year-over-year compared to FY 2024. Operating income came in at $254M.
In Q3 2025, Alkermes plc. reported revenue of $394M and earnings per share (EPS) of $0.50. Net income for the quarter was $83M. Gross margin was 86.9%. Revenue grew 4.2% year-over-year compared to Q3 2024. Operating income came in at $89M.
In Q2 2025, Alkermes plc. reported revenue of $391M and earnings per share (EPS) of $0.53. Net income for the quarter was $87M. Gross margin was 87.3%. Revenue grew -2.1% year-over-year compared to Q2 2024. Operating income came in at $93M.
Over the past 8 quarters, Alkermes plc. has demonstrated a growth trajectory, with revenue expanding from $399M to $1.47B. Investors analyzing ALKS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ALKS Dividend Yield and Income Analysis
Alkermes plc. (ALKS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ALKS Momentum and Technical Analysis Profile
Alkermes plc. (ALKS) has a momentum factor score of 45/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ALKS vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Alkermes plc. (ALKS) ranks #62 out of 838 stocks based on the Blank Capital composite score. This places ALKS in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ALKS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALKS vs S&P 500 (SPY) comparison to assess how Alkermes plc. stacks up against the broader market across all factor dimensions.
ALKS Next Earnings Date
No upcoming earnings date has been announced for Alkermes plc. (ALKS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ALKS? — Investment Thesis Summary
Alkermes plc. presents a balanced picture with arguments on both sides.
In summary, Alkermes plc. (ALKS) earns a Hold rating with a composite score of 44.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALKS stock.
Related Resources for ALKS Investors
Explore more research and tools: ALKS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALKS head-to-head with peers: ALKS vs AZN, ALKS vs SLGL, ALKS vs VMD.